Baxter price target lowered to $23 from $24 at Evercore ISI

Evercore ISI analyst Vijay Kumar lowered the firm’s price target on Baxter (BAX) to $23 from $24 and keeps an Outperform rating on the shares. Recovering end markets and sector rotation have “set the stage for a 2026 Tools play,” the analyst tells investors. In MedTech, the firm’s survey work points to healthy procedure and CapEx trends into 2026 and early recovery signs in China support the group, but sector rotation and potential ACA and Medicare changes “have bears watching,” the analyst added.